CC chemokines family in fibrosis and aging: From mechanisms to therapy
Wangrui Lei,Liyuan Jia,Zheng Wang,Zhenxing Liang,Zhao Aizhen,Yanqing Liu,Ye Tian,Lin Zhao,Yawu Chen,Guangyong Shi,Zhi Yang,Yang Yang,Xuezeng Xu
DOI: https://doi.org/10.1016/j.arr.2023.101900
IF: 11.788
2023-06-01
Ageing Research Reviews
Abstract:Fibrosis is a universal aging-related pathological process in the different organ, but is actually a self-repair excessive response. To date, it still remains a large unmet therapeutic need to restore injured tissue architecture without detrimental side effects, due to the limited clinical success in the treatment of fibrotic disease. Although specific organ fibrosis and the associated triggers have distinct pathophysiological and clinical manifestations, they often share involved cascades and common traits, including inflammatory stimuli, endothelial cell injury, and macrophage recruitment. These pathological processes can be widely controlled by a kind of cytokines, namely chemokines. Chemokines act as a potent chemoattractant to regulate cell trafficking, angiogenesis, and extracellular matrix (ECM). Based on the position and number of N-terminal cysteine residues, chemokines are divided into four groups: the CXC group, the CX3C group, the (X)C group, and the CC group. The CC chemokine classes (28 members) is the most numerous and diverse subfamily of the four chemokine groups. In this Review, we summarized the latest advances in the understanding of the importance of CC chemokine in the pathogenesis of fibrosis and aging and discussed potential clinical therapeutic strategies and perspectives aimed at resolving excessive scarring formation.
cell biology,geriatrics & gerontology,gerontology